The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies: A case report.
Miaomiao ZhaoXiya GuiQiuling WuLinghui XiaYadan WangPublished in: Medicine (2021)
Multidrug-resistant mutations within the BCR-ABL1 kinase domain are an emerging clinical problem for patients receiving sequential TKIs therapy. Acquisition of E255K/V-inclusive mutations is usually associated with ponatinib resistance, thus it is necessary to screen out new real pan-inhibitor compounds for all BCR/ABL mutations and figure out the potential efficacy of asciminib-based drug combinations in the future.
Keyphrases
- acute lymphoblastic leukemia
- chronic myeloid leukemia
- tyrosine kinase
- multidrug resistant
- allogeneic hematopoietic stem cell transplantation
- high throughput
- escherichia coli
- stem cells
- mesenchymal stem cells
- gram negative
- cystic fibrosis
- climate change
- current status
- klebsiella pneumoniae
- acinetobacter baumannii
- risk assessment
- electronic health record